Clinical TrialJun 15, 2026, 08:01 AM
OPKO Biologics Presents Strong Preclinical Data for Acromegaly Drug
AI Summary
OPKO Health's subsidiary, OPKO Biologics, presented positive preclinical data for OPK8801001, a novel long-acting hGH receptor antagonist for acromegaly, at ENDO 2026. The data demonstrated robust, dose-dependent, and sustained suppression of IGF-1 in vivo, suggesting a potential once-weekly treatment option. Furthermore, in vitro studies showed OPK8801001 to be approximately 20-fold more potent than Pegvisomant, a current daily therapy, indicating a significant improvement in treatment burden for patients with this rare endocrine disorder.
Key Highlights
- OPKO Biologics presented preclinical data for OPK8801001 at ENDO 2026.
- OPK8801001 is a novel long-acting hGH receptor antagonist for acromegaly.
- In vivo data showed robust, dose-dependent, sustained suppression of IGF-1.
- Findings suggest potential for a weekly alternative to current daily treatments.
- In vitro data showed OPK8801001's potency is approximately 20-fold greater than Pegvisomant.
- OPK8801001 could reduce the burden of daily therapy for acromegaly patients.
Price Impact
More from OPK